Author

J. M. Spangle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. L. Hong· 2 shared A. H. Corbett· 1 shared A. J. Murphy· 1 shared A. L. Christie· 1 shared B. A. Leeper· 1 shared B. Crompton· 1 shared B. D. Kynnap· 1 shared B. Dwivedi· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. L. Hong

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotype

K. Sad, C. Y. Jones, D. V. Fawwal, E. J. Hill, K. Skinner, S. Lustenberger, R. S. Lee, S. R. Elayavalli, J. Farhi, L. D. Lemon, M. B. Fasken, A. L. Hong, S. A. Sloan, A. H. Corbett, J. M. Spangle

This paper shows that the H3E50K mutation in histone H3 promotes oncogenic activity by enhancing cell migration, invasion, and epithelial-mesenchymal transition.

bioRxiv · Oct 11, 2023 · PreprintCancer Biology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology